Advancing Non-Systemic Medicines for Inflammatory Skin Diseases
Turn Therapeutics develops first-in-class topical cytokine-modulating therapeutics designed to deliver targeted anti-inflammatory effects without systemic immune exposure or injections.
Turn Therapeutics is a clinical-stage biotechnology company advancing first-in-class targeted therapies designed to act where disease occurs, not where it does not.
Our approach is grounded in a simple principle: effective medicine should deliver therapeutic impact locally, without unnecessary systemic exposure.
We are building a new category of precision therapeutics that combine biologic-level efficacy with localized delivery, beginning in dermatologic inflammation.
Breakthrough Science, Precisely Where It Is Needed
A Promising Therapeutic Direction for Inflammatory Skin Diseases
Currently approved moderate-to-severe eczema treatments primarily rely on systemic injectable biologics that suppress immune function throughout the entire body – not just where inflammation occurs. This can lead to unwanted serious side effects that may contribute to the interruption or discontinuation of therapy.
The Result
Burden of
systemic biologics
Growing demand
for alternatives
Localized
cytokine modulation
GX-03: A First-in-Class Topical Modulator of
IL-36 and Key Downstream Cytokines
GX-03 targets IL-36α, IL-36γ, IL-31, and IL-4 — central drivers of itch and inflammation in eczema — delivering strong anti-inflammatory effects directly to the site without systemic exposure.
Capital-Efficient Execution
Our business model combines a focused clinical pipeline with strategic partnerships that generate non-dilutive revenue. This approach validates our operational capabilities and enables sustained investment in GX-03 development.
